CN102740889A - 用于预防或抑制艰难梭菌感染的疗法 - Google Patents

用于预防或抑制艰难梭菌感染的疗法 Download PDF

Info

Publication number
CN102740889A
CN102740889A CN2010800537789A CN201080053778A CN102740889A CN 102740889 A CN102740889 A CN 102740889A CN 2010800537789 A CN2010800537789 A CN 2010800537789A CN 201080053778 A CN201080053778 A CN 201080053778A CN 102740889 A CN102740889 A CN 102740889A
Authority
CN
China
Prior art keywords
toxin
antibody
trypsin
clostridium difficile
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800537789A
Other languages
English (en)
Chinese (zh)
Inventor
克利福德·肖恩
埃普丽尔·罗伯茨
约翰·兰登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Department Of Health And Social Security
Mccrofom Co Ltd
Original Assignee
Health Protection Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2010/050288 external-priority patent/WO2010094970A1/en
Application filed by Health Protection Agency, Micropharm Ltd filed Critical Health Protection Agency
Publication of CN102740889A publication Critical patent/CN102740889A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2010800537789A 2009-12-04 2010-12-06 用于预防或抑制艰难梭菌感染的疗法 Pending CN102740889A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0921288.7 2009-12-04
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins
GBPCT/GB2010/050288 2010-02-19
PCT/GB2010/052035 WO2011067616A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection

Publications (1)

Publication Number Publication Date
CN102740889A true CN102740889A (zh) 2012-10-17

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800537789A Pending CN102740889A (zh) 2009-12-04 2010-12-06 用于预防或抑制艰难梭菌感染的疗法

Country Status (10)

Country Link
US (1) US8921529B2 (enExample)
EP (1) EP2506877B1 (enExample)
JP (1) JP5877161B2 (enExample)
CN (1) CN102740889A (enExample)
BR (1) BR112012013496A2 (enExample)
CA (1) CA2782639C (enExample)
GB (1) GB0921288D0 (enExample)
MY (1) MY158712A (enExample)
SG (1) SG181127A1 (enExample)
WO (1) WO2011067616A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113846079A (zh) * 2015-07-24 2021-12-28 酶公司 新型胰蛋白酶同功异型物和其用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ZA201401683B (en) 2013-03-08 2017-06-28 Cipla Ltd Pharmaceutical compositions for rectal administration
US20160030542A1 (en) * 2013-03-15 2016-02-04 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
WO2002043767A1 (en) * 2000-11-30 2002-06-06 Unigene Laboratories Inc. Improved oral delivery of peptides using enzyme-cleavable membrane translocators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
US20070265187A1 (en) * 2004-04-29 2007-11-15 Slobodan Vukicevic Oral Formulations Comprising Bone Morphogenetic Proteins For Treating Metabolic Bone Diseases
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
WO2002043767A1 (en) * 2000-11-30 2002-06-06 Unigene Laboratories Inc. Improved oral delivery of peptides using enzyme-cleavable membrane translocators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREAS BERNKOP-SCHNURCH: "The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins", 《JOURNAL OF CONTROLLED RELEASE》 *
EL-RASHDY M. REDWAN: "Production and purification of ovine anti-tetanus antibody", 《COMPARATIVE IMMUNOLOGY, MICROBIOLOGY & INFECTIOUS DISEASES》 *
JOHN A. KINK: "Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective reatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection", 《 INFECTION AND IMMUNITY》 *
刘杨: "艰难梭菌相关性腹泻研究进展", 《中国感染与化疗杂志》 *
王兴民，邝欣，孟筱琦，王成怀: "酶联免疫吸附试验检测艰难梭菌A毒素", 《微生物学免疫学进展》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113846079A (zh) * 2015-07-24 2021-12-28 酶公司 新型胰蛋白酶同功异型物和其用途
CN113846079B (zh) * 2015-07-24 2024-12-03 酶公司 新型胰蛋白酶同功异型物和其用途

Also Published As

Publication number Publication date
JP5877161B2 (ja) 2016-03-02
US8921529B2 (en) 2014-12-30
BR112012013496A2 (pt) 2016-08-16
WO2011067616A1 (en) 2011-06-09
EP2506877A1 (en) 2012-10-10
US20130004561A1 (en) 2013-01-03
EP2506877B1 (en) 2021-08-04
SG181127A1 (en) 2012-07-30
AU2010325764A1 (en) 2012-06-07
MY158712A (en) 2016-11-15
JP2013512889A (ja) 2013-04-18
GB0921288D0 (en) 2010-01-20
CA2782639C (en) 2019-02-26
CA2782639A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
CA2782639C (en) Therapies for preventing or suppressing clostridium difficile infection
JP5740714B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
JP3914484B2 (ja) 可溶性組換えボツリヌス毒素タンパク
US20100150942A1 (en) Affinity purified human polyclonal antibodies and methods of making and using them
JPH11506424A (ja) ベロ毒素産生大腸菌に対する治療
CN113289012B (zh) 治疗和/或预防艰难梭菌相关疾病的方法和组合物
Zhang et al. Potential therapeutic effects of egg yolk antibody (Igy) in helicobacter pylori infections─ A review
JP2022046576A (ja) 炎症性障害の治療療法
Sanchez et al. Inhibition of adhesion of enterotoxigenic Escherichia coli cells expressing F17 fimbriae to small intestinal mucus and brush-border membranes of young calves
AU2010325764B2 (en) Therapies for preventing or suppressing Clostridium difficile infection
KR100435829B1 (ko) 수크라아제와 말타아제에 대한 난황항체의 생산방법 및이를 이용한 식이 탄수화물의 흡수 억제용 조성물
HK1173646A (en) Therapies for preventing or suppressing clostridium difficile infection
HK1173646B (en) Therapies for preventing or suppressing clostridium difficile infection
RO138173A2 (ro) Utilizarea imunoglobulinelor y în tratamentul fibrozei chistice-infecţia cu pseudomonas aeruginosa, a infecţiei cu mycobacterium tuberculosis şi infecţiei cu helicobacter pylori
KR100497700B1 (ko) 용해성재조합보툴리누스독소단백질
KR20030063972A (ko) 나트륨 의존성 포도당 운반체에 대한 난황항체의 생산방법및 이를 이용한 식이 탄수화물의 흡수 억제용 조성물
AU2521600A (en) Treatment for verotoxin-producing escherichia coli

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161128

Address after: London, England

Applicant after: BMH

Applicant after: Micropharm Limited

Address before: Wiltshire

Applicant before: Health Protection Agency

Applicant before: Micropharm Limited

RJ01 Rejection of invention patent application after publication

Application publication date: 20121017

RJ01 Rejection of invention patent application after publication
TA01 Transfer of patent application right

Effective date of registration: 20220307

Address after: London

Applicant after: Department of health and social security

Applicant after: Mccrofom Co., Ltd

Address before: London

Applicant before: THE SECRETARY OF STATE FOR HEALTH

Applicant before: Mccrofom Co., Ltd

TA01 Transfer of patent application right